IMAB250117C5000
- 0.00
- 0.000.00%
I-Mab Newsroom
Express News | Significant progress in domestically produced growth hormone! Hubei Jumpcan Pharmaceutical and i-mab announced that the application for the market launch of Itan long-acting growth hormone has been accepted.
Hua Chuang Securities interprets the December Politburo meeting: five unexpected points.
① The first expectation exceeded - the economic development goals for the entire year of 2024 will be achieved. ② The second expectation exceeded - stabilizing the stock market and real estate market. ③ The third expectation exceeded - the monetary policy is set to undergo a significant change over the next decade. ④ The fourth expectation exceeded - strengthening "extraordinary" counter-cyclical adjustments. ⑤ The fifth expectation exceeded - expanding domestic demand ranking is advanced, and the保障民生保障 is intensified.
Tonight, Chinese concepts soared! The nasdaq Golden Dragon index surged by 10%, while fangdd network doubled directly.
Some analysis indicates that the Political Bureau meeting first mentioned stabilizing the stock and real estate markets, and the US stock market quickly rallied on china assets. The 3x Long FTSE china etf surged over 26%, the 2x Long china internet plus-related stocks rose over 22%, the 2x Long FTSE china 50 ETF increased over 17%, and the 2x Long 300etf gained nearly 15%.
Bullish surprise! A50 and Hong Kong stocks surged, china assets etf collectively skyrocketed, and the 3x long FTSE china etf jumped nearly 18% in pre-market trading.
Just now, the Hong Kong stock market surged sharply, with the hang seng tech index rising over 4% and the hang seng index increasing by 2%. The ftse china a50 index futures also surged, at one point rising over 4%.
The Political Bureau of the Central Committee of the Communist Party of China: Implement more proactive macro policies, expand domestic demand, promote the integration of technology innovation and industrial innovation, and stabilize the real estate and s
The Political Bureau of the CPC Central Committee held a meeting on December 9 to analyze and study the economic work in 2025; listened to the work report of the Central Commission for Discipline Inspection and State Supervision Commission, and discussed the arrangements for the party's work style and anti-corruption work in 2025. General Secretary of the CPC Central Committee **** presided over the meeting.
I-Mab Leads Our Spotlight On 3 US Penny Stocks
I-Mab Biopharma's Strategic Shift to US-Based Biotech
I-Mab to Participate at the Piper Sandler Healthcare Conference
I-Mab Third Quarter 2024 Earnings: US$0.25 Loss per Share (Vs US$0.57 Loss in 3Q 2023)
I-Mab's Third Quarter Results: Progress in Cancer Immunotherapies
H.C. Wainwright Maintains I-Mab(IMAB.US) With Buy Rating, Maintains Target Price $8
I-MAB Receives Buy Rating as Uliledlimab and Givastomig Show Promising Clinical Progress
HC Wainwright & Co. Reiterates Buy on I-MAB, Maintains $8 Price Target
I-MAB Analyst Ratings
IMAB Q3 GAAP EPS Of $(0.11) Vs. $(0.04) YoY, Cash And Cash Equivalents, And Short-term Investments Of $184.4M Expected To Be Sufficient To Fund Its Current Operating Plan Into 2027
Express News | I-Mab: Estimated Cash Runway Into 2027, Based on $184.4 Mln in Cash & Cash Equivalents, & Short-Term Investments as of Sept30, 2024
I-Mab 3Q Rev $0.00 >IMAB
I-Mab | 6-K: Report of foreign private issuer (related to financial reporting)
I-Mab Biopharma GAAP EPS of -$0.11 Misses by $0.04
I-Mab Q3 Loss Declines